US Tox21 to begin screening 10,000 chemicals

December 7, 2011

A high-speed robotic screening system, aimed at protecting human health by improving how chemicals are tested in the United States, begins today to test 10,000 compounds for potential toxicity. The compounds cover a wide variety of classifications, and include consumer products, food additives, chemicals found in industrial processes, and human and veterinary drugs. A complete list of the compounds is publicly available at http://www.epa.gov/ncct/dsstox.

Testing this 10,000 compound library begins a new phase of an ongoing collaboration between the National Institutes of Health, the U.S. , and the U.S. , referred to as Tox21. NIH partners include the National Toxicology Program (NTP), administered by the National Institute of (NIEHS), and the NIH Genomics Center (NCGC), part of the NIH Center for Translational Therapeutics (NCTT), housed at the National Institute (NHGRI).

"There has never been a compound library like this before," said NIEHS/NTP Director Linda Birnbaum, Ph.D.

Birnbaum is especially excited that some of the compounds the NTP has brought forward for testing are mixtures of chemicals. "All of us are exposed to many different chemicals at the same time, not just one chemical at a time," she said. "These new technologies allow us to more rapidly advance our understanding of not only individual chemicals, but mixtures of chemicals as well."

A subset of the NTP portion of the 10,000 compound library will focus on pilot testing several formulations or mixtures of compounds, a priority area for NIEHS/NTP. The library constituents were selected after a thorough analysis of existing scientific studies, more than 200 public chemical databases, and chemical nominations received from internal and external partners. Each test compound will undergo a thorough chemical analysis to verify its identity and determine its purity, concentration, and stability.

The goal of the testing is to provide results that will be useful for evaluating if these chemicals have the potential to disrupt processes in the human body to an extent that leads to adverse health effects.

The compounds will be tested in the Tox21 robotic screening system at the NCGC in Rockville, Md. The Tox21 robot, unveiled earlier this year, was purchased with funds provided by the NTP as part of its contribution to the Tox21 partnership.

"The robot has undergone rigorous testing since it was installed and unveiled earlier this year. It's ready to start testing this large compound library," said NHGRI Director Eric Green, M.D., Ph.D. "This is a milestone for Tox21, because it will allow us to test chemicals at a rate previously impossible for anyone to do by hand."

The development of methods for evaluating chemical toxicity has the potential to revolutionize the assessment of new environmental chemicals and the development of new drugs for therapeutic use.

"We are happy to contribute NCGC's pharmaceutical collection of approximately 3,500 compounds of approved and investigational drugs as part of the Tox21 program," said NCTT Scientific Director Christopher Austin, M.D. "Drug toxicity is one of the primary reasons that the development of new drugs fails and approved drugs are removed from the market, and the ability to better predict toxicity would improve the efficiency of drug development enormously."

The EPA seeks to understand the molecular basis of such chemicals to better protect human health and that of the environment.

"The Tox21 partnership integrates revolutionary advances in molecular biology, chemistry, and computer science, to quickly and cost-effectively screen the thousands of chemicals in use today," said Paul Anastas, Ph.D., assistant administrator of the EPA Office of Research and Development. "The innovative robotics screening technology will generate chemical toxicity data that EPA has never had before."

The FDA, also a partner in Tox21, emphasizes the value of this effort for the public. "The Tox21 rapid assessment of drug toxicity can become a powerful safety tool for protecting the American public. It also has the potential to help bring innovative drugs to market by allowing drug developers to identify unsafe candidate drugs early," said Janet Woodcock, M.D., director of the FDA Center for Drug Evaluation and Research.

Explore further: NIH researchers create comprehensive collection of approved drugs to identify new therapies

More information: All testing results will be available to the public through NIH and EPA chemical toxicity databases. In addition, NCTT has created a Tox21 chemical inventory browser freely available at tripod.nih.gov/tox21chem to provide researchers with additional about the chemicals. For more information about Tox21, visit www.niehs.nih.gov/health/asset … cs_p_z/ntp-tox21.pdf

Related Stories

NIH researchers create comprehensive collection of approved drugs to identify new therapies

April 27, 2011
Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label ...

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.